The role of peripherally acting mu-opioid receptor antagonists (PAMORA) in the treatment of constipation in palliative care

Tomasz Dzierżanowski

doi:10.5114/pm.2019.86528

eISSN: 2081-2833
ISSN: 2081-0016

Medycyna Paliatywna/Palliative Medicine

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

2/2019
vol. 11

Send email

Copy url:

abstract:

Review paper

The role of peripherally acting mu-opioid receptor antagonists (PAMORA) in the treatment of constipation in palliative care

Tomasz Dzierżanowski

¹

Pracownia Medycyny Paliatywnej, Zakład Medycyny Społecznej i Zdrowia Publicznego, Warszawski Uniwersytet Medyczny

Medycyna Paliatywna 2019; 11(2): 51-57

DOI: https://doi.org/10.5114/pm.2019.86528

Online publish date: 2019/07/18

View full text Get citation

PlumX metrics:

Opioid-induced constipation (OIC) is the most common adverse effect of opioid analgesics. Its treatment is difficult and depends to a large extent on multiple overlapping dietary, behavioral, disease-related, and iatrogenic causes. The prevention of constipation is mandatory, along with the initiation of opioid use. In the treatment of OIC, regular laxatives are recommended, despite their poor effectiveness. In the case of ineffectiveness, one of the peripherally acting m opioid receptor antagonists (PAMORA), such as methylnaltrexone, naloxegol, or naldemedine, should be used. After achieving bowel movements, the treatment with antagonist should be continued.

keywords:

The role of peripherally acting mu-opioid receptor antagonists (PAMORA) in the treatment of constipation in palliative care

Tomasz Dzierżanowski 1

constipation, palliative care, peripherally acting m opioid receptor antagonists, PAMORA

Tomasz Dzierżanowski

¹